

Ardex (Ardex NZ)

Chemwatch: **4861-68** Version No: **2.1.1.1** Safety Data Sheet according to HSNO Regulations Chemwatch Hazard Alert Code: 2

Issue Date: **19/09/2013** Print Date: **04/06/2014** Initial Date: **Not Available** S.GHS.NZL.EN

SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING

Product Identifier

Product name	Dunlop Ardit Crack Filler	
Chemical Name	Not Applicable	
Synonyms	Not Available	
Proper shipping name	Not Applicable	
Chemical formula	Not Applicable	
Other means of identification	Not Available	
CAS number	Not Applicable	

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Use according to manufacturer's directions.
--------------------------	---

Details of the supplier of the safety data sheet

Registered company name	Ardex (Ardex NZ)	Ardex (Ardex Australia)
Address	32 Lane Street Woolston Christchurch New Zealand	20 Powers Road Seven Hills 2147 NSW Australia
Telephone	+64 3384 3029	1800 224 070
Fax	+64 3384 9779	+61 2 9838 7817
Website	Not Available	Not Available
Email	Not Available	Not Available

Emergency telephone number

Association / Organisation	Not Available	Not Available	
Emergency telephone numbers	1800 222 841 (General information)	1800 222 841	
Other emergency telephone numbers	1800 222 841 (General information)	1800 222 841	

SECTION 2 HAZARDS IDENTIFICATION

Classification of the substance or mixture

Considered a Hazardous Substance according to the criteria of the New Zealand Hazardous Substances New Organisms legislation. Not regulated for transport of Dangerous Goods.

CHEMWATCH HAZARD RATINGS

	Min	Max	
Flammability	1 🔜	1	
Toxicity	2	0 = Minim	um
Body Contact	2	1 = Low	um
Reactivity	2	2 = Mode 3 = High	rate
Chronic	2	4 = Extrer	ne

 GHS Classification [1]
 Acute Toxicity (Inhalation) Category 4, Skin Corrosion/Irritation Category 2, Eye Irritation Category 2A, Respiratory Sensitizer Category 1, Skin Sensitizer Category 1, Germ Cell Mutagen Category 2, Carcinogen Category 2, STOT - SE (Resp. Irr.) Category 3, STOT - RE Category 2

Chemwatch: **4861-68** Version No: **2.1.1.1** Page 2 of 13
Dunlop Ardit Crack Filler

Legend:	1. Classified by Chemwatch; 2. Classification drawn from CCID EPA NZ ; 3. Classification drawn from EC Directive 1272/2008 - Annex VI
Determined by Chemwatch using GHS/HSNO criteria	6.1D (inhalation), 6.3A, 6.4A, 6.5A (respiratory), 6.5B (contact), 6.6B, 6.7B, 6.9 (respiratory), 6.9B (inhalation)

Label elements

GHS label elements	

SIGNAL WORD DANGER

Hazard statement(s)

H332	Harmful if inhaled	
H315	Causes skin irritation	
H319	H319 Causes serious eye irritation	
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled	
H317	May cause an allergic skin reaction	
H341	Suspected of causing genetic defects	
H351	Suspected of causing cancer	
H335	May cause respiratory irritation	
H373	May cause damage to organs through prolonged or repeated exposure	

Precautionary statement(s): Prevention

P201	Obtain special instructions before use.	
P260	Do not breathe dust/fume/gas/mist/vapours/spray.	
P271	P271 Use only outdoors or in a well-ventilated area.	
P280	P280 Wear protective gloves/protective clothing/eye protection/face protection.	

Precautionary statement(s): Response

P304+P340	P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.	
P308+P313	IF exposed or concerned: Get medical advice/attention.	
P321	Specific treatment (see advice on this label).	
P342+P311 If experiencing respiratory symptoms: Call a POISON CENTER/doctor/physician/first aider		

Precautionary statement(s): Storage

P405	Store locked up.	
P403+P233	Store in a well-ventilated place. Keep container tightly closed.	

Precautionary statement(s): Disposal

Dispose of contents/container to authorised chemical landfill or if organic to high temperature incineration

SECTION 3 COMPOSITION / INFORMATION ON INGREDIENTS

P501

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
9016-87-9	<50	polymeric diphenylmethane diisocyanate
6846-50-0	<40	2,2,4-trimethyl-1,3-pentanediol diisobutyrate
101-68-8	<20	4,4'-diphenylmethane diisocyanate (MDI)
6846-50-0	<50	2,2,4-trimethyl-1,3-pentanediol diisobutyrate
102-60-3	<25	tetrahydroxypropyl ethylenediamine

Chemwatch: 4861-68		Page 3 of 13		Issue Date: 19/09/2013
Version No: 2.1.1.1		Dunlop Ardit Crack Filler		Print Date: 04/06/2014
	-			
25791-96-2	<20	polypropylene glycol glyceryl ether		
110-63-4	<6	1,4-butylene glycol		

SECTION 4 FIRST AID MEASURES

NZ Poisons Centre 0800 POISON (0800 764 766) | NZ Emergency Services: 111

Description of first aid measures

Eye Contact	 If this product comes in contact with the eyes: Wash out immediately with fresh running water. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. Seek medical attention without delay; if pain persists or recurs seek medical attention. Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	 If skin contact occurs: Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation.
Inhalation	 If fumes or combustion products are inhaled remove from contaminated area. Lay patient down. Keep warm and rested. Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures. Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary. Transport to hospital, or doctor, without delay. Following uptake by inhalation, move person to an area free from risk of further exposure. Oxygen or artificial respiration should be administered as needed. Asthmatic-type symptoms may develop and may be immediate or delayed up to several hours. Treatment is essentially symptomatic. A physician should be consulted.
Ingestion	 For advice, contact a Poisons Information Centre or a doctor at once. Urgent hospital treatment is likely to be needed. If swallowed do NOT induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. Observe the patient carefully. Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. Transport to hospital or doctor without delay.

Indication of any immediate medical attention and special treatment needed

 Treat symptomatically. For sub-chronic and chronic exposures to isocyanates: This material may be a potent pulmonary sensitiser which causes bronchospasm even in patients without prior airway hyperreactivity. Clinical symptoms of exposure involve mucosal irritation of respiratory and gastrointestinal tracts. Conjunctival irritation, skin inflammation (erythema, pain vesiculation) and gastrointestinal disturbances occur soon after exposure. Pulmonary symptoms include cough, burning, substernal pain and dyspnoea. Some cross-sensitivity occurs between different isocyanates. Noncardiogenic pulmonary oedema and bronchospasm are the most serious consequences of exposure. Markedly symptomatic patients should receive oxygen, ventilatory support and an intravenous line. Treatment for asthma includes inhaled sympathomimetics (epinephrine [adrenalin], terbutaline) and steroids. Activated charcoal (1 g/kg) and a cathartic (sorbitol, magnesium citrate) may be useful for ingestion. Mydriatics, systemic analgesics and topical antibiotics (Sulamyd) may be usef for corneal abrasions. There is no effective therapy for sensitised workers. [Ellenhorm and Barceloux; Medical Toxicology] NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the concentration and duration of exposure. They induces smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory diseese, asthmatic or bronchial attacks, indications of allergic r	•	•
 This material may be a potent pulmonary sensitiser which causes bronchospasm even in patients without prior airway hypereactivity. Clinical symptoms of exposure involve mucosal irritation of respiratory and gastrointestinal tracts. Conjunctival irritation, skin inflammation (erythema, pain vesiculation) and gastrointestinal disturbances occur soon after exposure. Pulmonary symptoms include cough, burning, substernal pain and dyspnoea. Some cross-sensitivity occurs between different isocyanates. Noncardiogenic pulmonary oedema and bronchospasm are the most serious consequences of exposure. Markedly symptomatic patients should receive oxygen, ventilatory support and an intravenous line. Treatment for asthma includes inhaled sympathomimetics (epinephrine [adrenalin], terbutaline) and steroids. Activated charcoal (1 g/kg) and a cathartic (sorbitol, magnesium citrate) may be useful for ingestion. Mydriatics, systemic analgesics and topical antibiotics (Sulamyd) may be used for corneal abrasions. There is no effective therapy for sensitised workers. [Ellenhorm and Barceloux; Medical Toxicology] NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the concentration and duration of exposure. They induce smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates; isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation condition		Treat symptomatically.
 prior airway hyperreactivity. Clinical symptoms of exposure involve mucosal irritation of respiratory and gastrointestinal tracts. Conjunctival irritation, skin inflammation (erythema, pain vesiculation) and gastrointestinal disturbances occur soon after exposure. Pulmonary symptoms include cough, burning, substernal pain and dyspnoea. Some cross-sensitivity occurs between different isocyanates. Noncardiogenic pulmonary oedema and bronchospasm are the most serious consequences of exposure. Markedly symptomatic patients should receive oxygen, ventilatory support and an intravenous line. Treatment for asthma includes inhaled sympathomimetics (epinephrine [adrenalin], terbutaline) and steroids. Activated charcoal (1 g/kg) and a cathartic (sorbitol, magnesium citrate) may be useful for ingestion. Mydriatics, systemic analgesics and topical antibiotics (Sulamyd) may be used for corneal abrasions. There is no effective therapy for sensitised workers. [Ellenhorn and Barceloux; Medical Toxicology] NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the concentration and duration of exposure. They induce smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who 		For sub-chronic and chronic exposures to isocyanates:
 Conjunctival irritation, skin inflammation (erythema, pain vesiculation) and gastrointestinal disturbances occur soon after exposure. Pulmonary symptoms include cough, burning, substernal pain and dyspnoea. Some cross-sensitivity occurs between different isocyanates. Noncardiogenic pulmonary oedema and bronchospasm are the most serious consequences of exposure. Markedly symptomatic patients should receive oxygen, ventilatory support and an intravenous line. Treatment for asthma includes inhaled sympathomimetics (epinephrine [adrenalin], terbutaline) and steroids. Activated charcoal (1 g/kg) and a cathartic (sorbitol, magnesium citrate) may be useful for ingestion. Mydriatics, systemic analgesics and topical antibiotics (Sulamyd) may be used for corneal abrasions. There is no effective therapy for sensitised workers. [Ellenhorn and Barceloux; Medical Toxicology] NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the concentration and duration of exposure. They induce smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, astimatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who 		
 occur soon after exposure. Pulmonary symptoms include cough, burning, substernal pain and dyspnoea. Some cross-sensitivity occurs between different isocyanates. Noncardiogenic pulmonary oedema and bronchospasm are the most serious consequences of exposure. Markedly symptomatic patients should receive oxygen, ventilatory support and an intravenous line. Treatment for asthma includes inhaled sympathomimetics (epinephrine [adrenalin], terbutaline) and steroids. Activated charcoal (1 g/kg) and a cathartic (sorbitol, magnesium citrate) may be useful for ingestion. Mydriatics, systemic analgesics and topical antibiotics (Sulamyd) may be used for corneal abrasions. There is no effective therapy for sensitised workers. [Ellenhorm and Barceloux; Medical Toxicology] NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the concentration and duration of exposure. They induce smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who 		Clinical symptoms of exposure involve mucosal irritation of respiratory and gastrointestinal tracts.
 Some cross-sensitivity occurs between different isocyanates. Noncardiogenic pulmonary oedema and bronchospasm are the most serious consequences of exposure. Markedly symptomatic patients should receive oxygen, ventilatory support and an intravenous line. Treatment for asthma includes inhaled sympathomimetics (epinephrine [adrenalin], terbutaline) and steroids. Activated charcoal (1 g/kg) and a cathartic (sorbitol, magnesium citrate) may be useful for ingestion. Mydriatics, systemic analgesics and topical antibiotics (Sulamyd) may be used for corneal abrasions. There is no effective therapy for sensitised workers. [Ellenhorn and Barceloux; Medical Toxicology] NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the concentration and duration of exposure. They induce smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who 		
 Noncardiogenic pulmonary oedema and bronchospasm are the most serious consequences of exposure. Markedly symptomatic patients should receive oxygen, ventilatory support and an intravenous line. Treatment for asthma includes inhaled sympathomimetics (epinephrine [adrenalin], terbutaline) and steroids. Activated charcoal (1 g/kg) and a cathartic (sorbitol, magnesium citrate) may be useful for ingestion. Mydriatics, systemic analgesics and topical antibiotics (Sulamyd) may be used for corneal abrasions. There is no effective therapy for sensitised workers. [Ellenhorn and Barceloux; Medical Toxicology] NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the concentration and duration of exposure. They induce smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who 		Pulmonary symptoms include cough, burning, substernal pain and dyspnoea.
Markedly symptomatic patients should receive oxygen, ventilatory support and an intravenous line. • Treatment for asthma includes inhaled sympathomimetics (epinephrine [adrenalin], terbutaline) and steroids. • Activated charcoal (1 g/kg) and a cathartic (sorbitol, magnesium citrate) may be useful for ingestion. • Mydriatics, systemic analgesics and topical antibiotics (Sulamyd) may be used for corneal abrasions. • There is no effective therapy for sensitised workers. [Ellenhorn and Barceloux; Medical Toxicology] NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the concentration and duration of exposure. They induce smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who		 Some cross-sensitivity occurs between different isocyanates.
 Activated charcoal (1 g/kg) and a cathartic (sorbitol, magnesium citrate) may be useful for ingestion. Mydriatics, systemic analgesics and topical antibiotics (Sulamyd) may be used for corneal abrasions. There is no effective therapy for sensitised workers. [Ellenhorn and Barceloux; Medical Toxicology] NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the concentration and duration of exposure. They induce smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who 		
 Mydriatics, systemic analgesics and topical antibiotics (Sulamyd) may be used for corneal abrasions. There is no effective therapy for sensitised workers. [Ellenhorn and Barceloux; Medical Toxicology] NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the concentration and duration of exposure. They induce smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who 		Treatment for asthma includes inhaled sympathomimetics (epinephrine [adrenalin], terbutaline) and steroids.
 There is no effective therapy for sensitised workers. [Ellenhorn and Barceloux; Medical Toxicology] NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the concentration and duration of exposure. They induce smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who 		Activated charcoal (1 g/kg) and a cathartic (sorbitol, magnesium citrate) may be useful for ingestion.
[Ellenhorn and Barceloux; Medical Toxicology] NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the concentration and duration of exposure. They induce smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who		Mydriatics, systemic analgesics and topical antibiotics (Sulamyd) may be used for corneal abrasions.
 NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the concentration and duration of exposure. They induce smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who 		There is no effective therapy for sensitised workers.
 concentration and duration of exposure. They induce smooth muscle contraction which leads to bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who 		[Ellenhorn and Barceloux; Medical Toxicology]
bronchoconstrictive episodes. Acute changes in lung function, such as decreased FEV1, may not represent sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who		NOTE: Isocyanates cause airway restriction in naive individuals with the degree of response dependant on the
sensitivity. [Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992] Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who		concentration and duration of exposure. They induce smooth muscle contraction which leads to
Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who		
medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who		[Karol & Jin, Frontiers in Molecular Toxicology, pp 56-61, 1992]
medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses, recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who		Personnel who work with isocyanates, isocyanate prepolymers or polyisocyanates should have a pre-placement
recurrent eczema or sensitisation conditions of the skin should not handle or work with isocyanates. Anyone who		medical examination and periodic examinations thereafter, including a pulmonary function test. Anyone with a
		medical history of chronic respiratory disease, asthmatic or bronchial attacks, indications of allergic responses,
		, , ,

has developed.

SECTION 5 FIREFIGHTING MEASURES

Extinguishing media

 Small quantities of water in contact with hot liquid may react violently with generation of a large volume of rapidly expanding hot sticky semi-solid foam. Presents additional hazard when fire fighting in a confined space. Cooling with flooding quantities of water reduces this risk.
Water spray or fog may cause frothing and should be used in large quantities.

Special hazards arising from the substrate or mixture

Fire Incompatibility	• Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc.
The incompatibility	as ignition may result

Advice for firefighters

Fire Fighting	 Alert Fire Brigade and tell them location and nature of hazard. Wear full body protective clothing with breathing apparatus. Prevent, by any means available, spillage from entering drains or water course. Use water delivered as a fine spray to control fire and cool adjacent area. 		
Fire/Explosion Hazard	 Combustible. Moderate fire hazard when exposed to heat or flame. When heated to high temperatures decomposes rapidly generating vapour which pressures and may then rupture containers with release of flammable and highly toxic isocyanate vapour. Burns with acrid black smoke and poisonous fumes. 		

SECTION 6 ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Minor Spills	 Slippery when spilt. Remove all ignition sources. Clean up all spills immediately. Avoid breathing vapours and contact with skin and eyes.
Major Spills	 Liquid Isocyanates and high isocyanate vapour concentrations will penetrate seals on self contained breathing apparatus - SCBA should be used inside encapsulating suit where this exposure may occur. For isocyanate spills of less than 40 litres (2 m2): Evacuate area from everybody not dealing with the emergency, keep them upwind and prevent further access, remove ignition sources and, if inside building, ventilate area as well as possible. Notify supervision and others as necessary. Put on personal protective equipment (suitable respiratory protection, face and eye protection, protective suit, gloves and impermeable boots).
	Personal Protective Equipment advice is contained in Section 8 of the MSDS.

SECTION 7 HANDLING AND STORAGE

Precautions for safe handling

i lecautions for sale nanuling	
Safe handling	 DO NOT allow clothing wet with material to stay in contact with skin Avoid all personal contact, including inhalation. Wear protective clothing when risk of exposure occurs. Use in a well-ventilated area. Prevent concentration in hollows and sumps.
Other information	 for commercial quantities of isocyanates: Isocyanates should be stored in adequately bunded areas. Nothing else should be kept within the same bunding. Pre-polymers need not be segregated. Drums of isocyanates should be stored under cover, out of direct sunlight, protected from rain, protected from physical damage and well away from moisture, acids and alkalis.

Conditions for safe storage, including any incompatibilities

Suitable container	 Metal can or drum Packaging as recommended by manufacturer.

Page 5 of 13
Dunlop Ardit Crack Filler

Issue Date: **19/09/2013** Print Date: **04/06/2014**

	 Check all containers are clearly labelled and free from leaks.
Storage incompatibility	 Avoid cross contamination between the two liquid parts of product (kit). If two part products are mixed or allowed to mix in proportions other than manufacturer's recommendation, polymerisation with gelation and evolution of heat (exotherm) may occur. This excess heat may generate toxic vapour Avoid any contamination of this material as it is very reactive and any contamination is potentially hazardous Esters react with acids to liberate heat along with alcohols and acids. Strong oxidising acids may cause a vigorous reaction with esters that is sufficiently exothermic to ignite the reaction products.

PACKAGE MATERIAL INCOMPATIBILITIES

Not Available

SECTION 8 EXPOSURE CONTROLS / PERSONAL PROTECTION

Control parameters

OCCUPATIONAL EXPOSURE LIMITS (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
New Zealand Workplace Exposure Standards (WES)	polymeric diphenylmethane diisocyanate	lsocyanates, all, (as -NCO)	0.02 mg/m3	0.07 mg/m3	Not Available	Sensitiser; These values apply to all isocyanates, including prepolymers, present in the workplace air as vapours, mist or dust.
New Zealand Workplace Exposure Standards (WES)	4,4'-diphenylmethane diisocyanate (MDI)	lsocyanates, all, (as -NCO)	0.02 mg/m3	0.07 mg/m3	Not Available	Sensitiser; These values apply to all isocyanates, including prepolymers, present in the workplace air as vapours, mist or dust.

EMERGENCY LIMITS

EMERGENCI LIMITS				
Ingredient	TEEL-0	TEEL-1	TEEL-2	TEEL-3
polymeric diphenylmethane diisocyanate	2 ppm	6 ppm	40 ppm	200 ppm
4,4'-diphenylmethane diisocyanate (MDI)	0.05 / 5 ppm	0.2 / 15 ppm	25 / 2 ppm	25 / 125 ppm
tetrahydroxypropyl ethylenediamine	15 ppm	50 ppm	350 ppm	500 ppm
polypropylene glycol glyceryl ether	10 ppm	30 ppm	200 ppm	500 ppm
1,4-butylene glycol	1.25 ppm	3.5 ppm	25 ppm	250 ppm
Ingredient	Original IDLH		Revised IDLH	
polymeric diphenylmethane diisocyanate	Not Available		Not Available	
2,2,4-trimethyl-1,3-pentanediol diisobutyrate	Not Available		Not Available	
4,4'-diphenylmethane diisocyanate (MDI)	100 mg/m3		75 mg/m3	
2,2,4-trimethyl-1,3-pentanediol diisobutyrate	Not Available		Not Available	
tetrahydroxypropyl ethylenediamine	Not Available		Not Available	
polypropylene glycol glyceryl ether	Not Available		Not Available	
1,4-butylene glycol	Not Available		Not Available	

Exposure controls

Appropriate engineering controls

• All processes in which isocyanates are used should be enclosed wherever possible.

▶ Total enclosure, accompanied by good general ventilation, should be used to keep atmospheric

Dunlop	Ardit	Crack	Filler
--------	-------	-------	--------

Other protection	All employees working with isocyanates must be informed of the hazards from exposure to the contaminant and the precautions necessary to prevent damage to their health. They should be made aware of the need to carry out their work so that as little contamination as possible is produced, and of the importance of the proper use of all safeguards against exposure to themselves and their fellow workers. Adequate training, both in the proper execution of the task and in the use of all associated engineering controls, as well as of any personal protective equipment, is essential. Employees exposed to contamination hazards should be educated in the need for, and proper use of, facilities, clothing and equipment and thereby maintain a high standard of personal cleanliness.
Body protection	See Other protection below
Hands/feet protection	 NOTE: The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact. Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed. The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer.
Skin protection	See Hand protection below
Eye and face protection	 Safety glasses with side shields. Chemical goggles. Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task.
Personal protection	
	 concentrations below the relevant exposure standards. If total enclosure of the process is not feasible, local exhaust ventilation may be necessary. Local exhaust ventilation is essential where lower molecular weight isocyanates (such as TDI or HDI) is used or where isocyanate or polyurethane is sprayed.

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the: "Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the computer-generated selection:

Dunlop Ardit Crack Filler

Material	СРІ
PE/EVAL/PE	A

* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion C: Poor to Dangerous Choice for other than short term immersion NOTE: As a series of factors will influence the actual performance of the

glove, a final selection must be based on detailed observation. -* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

Respiratory protection

Type A-P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required.

Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	A-AUS P2	-	A-PAPR-AUS / Class 1 P2
up to 50 x ES	-	A-AUS / Class 1 P2	-
up to 100 x ES	-	A-2 P2	A-PAPR-2 P2 ^

^ - Full-face

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

SECTION 9 PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

	slight odour; does not mix with water.		
Physical state	Liquid	Relative density (Water = 1)	1.069
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Applicable	Decomposition temperature	Not Available
Melting point / freezing point (°C)	<0 (MDI) (freezing point)	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	209	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	>199	Taste	Not Available
Evaporation rate	Non-Volatile	Explosive properties	Not Available
Flammability	Not Available	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Available	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Negligible	Gas group	Not Available
Solubility in water (g/L)	Reacts	pH as a solution(1%)	Not Applicable
Vapour density (Air = 1)	8.5 (MDI)	VOC g/L	Not Available

SECTION 10 STABILITY AND REACTIVITY

Reactivity	See section 7
Chemical stability	Unstable in the presence of incompatible materials. Product is considered stable. Hazardous polymerisation will not occur. Presence of elevated temperatures.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 TOXICOLOGICAL INFORMATION

Information on toxicological effects

Inhaled	Inhalation of aerosols (mists, fumes), generated by the material during the course of normal handling, may be harmful. Evidence shows, or practical experience predicts, that the material produces irritation of the respiratory system, in a substantial number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs.
Ingestion	Accidental ingestion of the material may be damaging to the health of the individual. Ingestion of 1,4-butylene glycol may cause central nervous system depression characterised by headache, dizziness, drowsiness, nausea, vomiting, abdominal pain and incoordination. Severe over-exposure may lead to coma and possible death due to respiratory failure. Ingestion may also cause kidney damage and peripheral neuropathy, a progressive disorder of the nervous system, characterised by sensory and motor abnormalities, muscle spasms, weakness and pain in the arms and legs, numbness and tingling of the fingers and toes and paralysis.
Skin Contact	 The material produces mild skin irritation; evidence exists, or practical experience predicts, that the material either produces mild inflammation of the skin in a substantial number of individuals following direct contact, and/or produces significant, but mild, inflammation when applied to the healthy intact skin of animals (for up to four hours), such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema)

epidermis.

which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the

	epidernia.		
Еуе	Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Repeated or prolonged eye contact may cause inflammation characterised by a temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.		
Chronic	On the basis, primarily, of animal experiments, concern has been expressed that the material may produce carcinogenic or mutagenic effects; in respect of the available information, however, there presently exists inadequate data for making a satisfactory assessment. Practical evidence shows that inhalation of the material is capable of inducing a sensitisation reaction in a substantial number of individuals at a greater frequency than would be expected from the response of a normal population. Pulmonary sensitisation, resulting in hyperactive airway dysfunction and pulmonary allergy may be accompanied by fatigue, malaise and aching. Significant symptoms of exposure may persist for extended periods, even after exposure ceases.		
Dunlop Ardit Crack Filler	TOXICITY	IRRITATION	
	Not Available	Not Available	
	TOXICITY	IRRITATION	
	Dermal (rabbit) LD50: >9400		
	mg/kg	Eye (rabbit): 100 mg - mild	
polymeric diphenylmethane diisocyanate	Inhalation (rat) LC50: 490 mg/m3/4h		
	Oral (rat) LD50: 43000 mg/kg		
	Not Available	Not Available	
	ΤΟΧΙΟΙΤΥ	IRRITATION	
	Dermal (Guinea pig) LD50: >20		
	ml/kg ***	**[Eastman] *[Patty]	
2,2,4-trimethyl-1,3-pentanediol	Inhalation (rat) LC50: >5.3 mg/l/6h**	Eye (rabbit): very slight**	
diisobutyrate	Oral (Mouse) LD50: >6400 mg/kg ***	Skin (guinea pig): 5000mg/kg-mild	
	Oral (rat) LD50: >3200 mg/kg*		
	Not Available	Not Available	
	ΤΟΧΙΟΙΤΥ	IRRITATION	
	Dermal (rabbit) LD50: >6200		
	mg/kg *	[* = Bayer CCINFO 2133615]	
4,4'-diphenylmethane diisocyanate (MDI)	Inhalation (Rat) LC50: 178 mg/m3	Dermal Sensitiser *	
	Oral (mouse) LD50: 2200 mg/kg	Respiratory Sensitiser (g.pig) *	
	Oral (Rat) LD50: 9200 mg/kg	Skin (rabbit): 500 mg /24 hours	
	Not Available	Not Available	
	TOXICITY	IRRITATION	
	Dermal (Guinea pig) LD50: >20 ml/kg ***	**[Eastman] *[Patty]	
2,2,4-trimethyl-1,3-pentanediol	Inhalation (rat) LC50: >5.3 mg/l/6h**	Eye (rabbit): very slight**	
diisobutyrate	Oral (Mouse) LD50: >6400 mg/kg ***	Skin (guinea pig): 5000mg/kg-mild	
	Oral (rat) LD50: >3200 mg/kg*		

tetrahydroxypropyl ethylenediamine	ΤΟΧΙΟΙΤΥ	IRRITATION
	Oral (rat) LD50: 3280 mg/kg *	Eye (rabbit): Non irritant *
		Skin (rabbit): Non irritant *
	Not Available	Not Available
	ΤΟΧΙΟΙΤΥ	IRRITATION
	Dermal (rabbit) LD50: >16000 mg/kg	Eye: non-irritant *
	Dermal (rabbit) LD50: >20000 mg/kg	Skin (rabbit): 500 mg (open)-mild
polypropylene glycol glyceryl ether	Inhalation (Rat) LC50: >200000 mg/m3/h *	
	Oral (mouse) LD50: 10000 mg/kg	
	Oral (rat) LD50: >64000 mg/kg	
	Oral (rat) LD50: 2830 mg/kg	
	Oral (Rat) LD50: 4000 mg/kg *	
	Not Available	Not Available
	ΤΟΧΙΟΙΤΥ	IRRITATION
	Intraperitoneal (mouse) LD50: 1650 mg/kg	
	Intraperitoneal (rat) LD50: 1070 mg/kg	
1,4-butylene glycol	Oral (g.pig) LD50: 1200 mg/kg	
	Oral (mouse) LD50: 2062 mg/kg	
	Oral (rabbit) LD50: 2531 mg/kg	
	Oral (rat) LD50: 1525 mg/kg	
	Not Available	Not Available

* Value obtained from manufacturer's msds

unless otherwise specified data extracted from RTECS - Register of Toxic Effects of Chemical Substances

Dunlop Ardit Crack Filler	No significant acute toxicological data identified in literature search.
POLYMERIC DIPHENYLMETHANE DIISOCYANATE	product
4,4'-DIPHENYLMETHANE DIISOCYANATE (MDI)	Inhalation (human) TCLo: 0.13 ppm/30 mins Eye (rabbit): 0.10 mg moderate
TETRAHYDROXYPROPYL ETHYLENEDIAMINE	Non mutagenic by Ames test * [BASF]
POLYPROPYLENE GLYCOL GLYCERYL ETHER	The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis. Data for Niax Polyol L-56 Data for Niax Polyol LG-168 * BASF Multranol 9175 SDS
POLYMERIC DIPHENYLMETHANE DIISOCYANATE, 4,4'-DIPHENYLMETHANE DIISOCYANATE (MDI)	The following information refers to contact allergens as a group and may not be specific to this product. Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody-mediated immune reactions.
2,2,4-TRIMETHYL- 1,3-PENTANEDIOL DIISOBUTYRATE	The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis. For 2,2,4-trimethyl-1,3-pentanediol diisobutyrate (TXIB)

Chemwatch: 4861-68 Version No: 2.1.1.1

Page 10 of 13

Dunlop Ardit Crack Filler

	TXIB showed no genotoxic effects ir	bacteria and chromosomal aberration	test <i>in vitro</i> .
2,2,4-TRIMETHYL- 1,3-PENTANEDIOL DIISOBUTYRATE	NOAEL oral (rat), 103 days = 1% in	diet ***	
2,2,4-TRIMETHYL- 1,3-PENTANEDIOL DIISOBUTYRATE	NOEL oral (dog), 90 days = 1% in diet ***		
2,2,4-TRIMETHYL- 1,3-PENTANEDIOL DIISOBUTYRATE	Mutagenicity/Genotoxicity Data: ***		
2,2,4-TRIMETHYL- 1,3-PENTANEDIOL DIISOBUTYRATE	Chromosomal aberration assay: Negative (, /- activation)		
2,2,4-TRIMETHYL- 1,3-PENTANEDIOL DIISOBUTYRATE	CHO/HGPRT assay: Negative (, /- activation)		
2,2,4-TRIMETHYL- 1,3-PENTANEDIOL DIISOBUTYRATE	Salmonella-E.coli reverse mutation assay (Ames test): Negative (, /- activation)		
2,2,4-TRIMETHYL- 1,3-PENTANEDIOL DIISOBUTYRATE	*,**,*** Various suppliers MSDS		
TETRAHYDROXYPROPYL ETHYLENEDIAMINE, 1,4-BUTYLENE GLYCOL	Asthma-like symptoms may continue for months or even years after exposure to the material ceases. This may be due to a non-allergenic condition known as reactive airways dysfunction syndrome (RADS) which can occur following exposure to high levels of highly irritating compound. Key criteria for the diagnosis of RADS include the absence of preceding respiratory disease, in a non-atopic individual, with abrupt onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. A reversible airflow pattern, on spirometry, with the presence of moderate to severe bronchial hyperreactivity on methacholine challenge testing and the lack of minimal lymphocytic inflammation, without eosinophilia, have also been included in the criteria for diagnosis of RADS.		
Acute Toxicity	v	Carcinogenicity	v
Skin Irritation/Corrosion	¥	Reproductivity	0
Serious Eye Damage/Irritation	✓	STOT - Single Exposure	✓
Respiratory or Skin	•	STOT - Repeated Exposure	~

CMR STATUS

Not Applicable

SECTION 12 ECOLOGICAL INFORMATION

sensitisation

Mutagenicity

¥

Toxicity

DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
Not Available	Not Available	Not Available
Bioaccumulative potential		
Ingredient	Bioaccumulation	
Not Available	Not Available	
Mobility in soil		
Ingredient	Mobility	
Not Available	Not Available	

STOT - Repeated Exposure

Aspiration Hazard

 \odot

SECTION 13 DISPOSAL CONSIDERATIONS

	 Containers may still present a chemical hazard/ danger when empty. Return to supplier for reuse/ recycling if possible. Otherwise:
Product / Packaging disposal	 If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.
	Where possible retain label warnings and MSDS and observe all notices pertaining to the product.
	Insure that the disposal of material is carried out in accordance with Hazardous Substances (Disposal) Regulation 2001.

SECTION 14 TRANSPORT INFORMATION

Marine Pollutant NO HAZCHEM Not Applicable

Land transport (UN): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL 73 / 78 and the IBC code

Source	Ingredient	Pollution Category	Residual Concentration - Outside Special Area (% w/w)	Residual Concentration
40-7-4-9-0-0-MK-20041022	1,4-butylene glycol	Not Available	Not Available	Not Available

SECTION 15 REGULATORY INFORMATION

Safety, health and environmental regulations / legislation specific for the substance or mixture

This substance is to be managed using the conditions specified in an applicable Group Standard

HSR Number	Group Standard
HSR002596	Laboratory Chemicals and Reagent Kits Group Standard 2006
HSR002531	Cleaning Products (Toxic [6.7]) Group Standard 2006
HSR002607	Lubricants (Toxic [6.7]) Group Standard 2006
HSR002520	Aerosols (Toxic [6.7]) Group Standard 2006
HSR002521	Animal Nutritional and Animal Care Products Group Standard 2006
HSR002586	Fuel Additives (Toxic [6.7]) Group Standard 2006
HSR002646	Polymers (Toxic [6.7]) Group Standard 2006
HSR002647	Reagent Kits Group Standard 2006
HSR002616	Metal Industry Products (Toxic [6.7]) Group Standard 2006
HSR002625	N.O.S. (Toxic [6.1, 6.7]) Group Standard 2006
HSR002639	Photographic Chemicals (Toxic [6.7]) Group Standard 2006
HSR002512	Additives, Process Chemicals and Raw Materials (Toxic [6.7]) Group Standard 2006
HSR002560	Dental Products (Toxic [6.7]) Group Standard 2006
HSR002568	Embalming Products (Toxic [6.7]) Group Standard 2006
HSR002679	Surface Coatings and Colourants (Toxic [6.7]) Group Standard 2006
HSR002687	Water Treatment Chemicals (Toxic [6.7]) Group Standard 2006
HSR100425	Pharmaceutical Active Ingredients Group Standard 2010
HSR002601	Leather and Textile Products (Toxic [6.7]) Group Standard 2006
HSR002551	Corrosion Inhibitors (Toxic [6.7]) Group Standard 2006

Issue Date: **19/09/2013** Print Date: **04/06/2014**

Dunlop	Ardit	Crack	Filler
--------	-------	-------	--------

HSR002552	Cosmetic Products Group Standard 2006	
HSR002648	Refining Catalysts Group Standard 2006	
HSR002655	Solvents (Toxic [6.7]) Group Standard 2006	
polymeric diphenylmethane diisocyanate(9016-87-9) is found on the following regulatory lists	"New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data", "New Zealand Inventory of Chemicals (NZIoC)", "OECD List of High Production Volume (HPV) Chemicals", "International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs", "New Zealand Workplace Exposure Standards (WES)", "OECD Existing Chemicals Database", "GESAMP/EHS Composite List - GESAMP Hazard Profiles", "New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals", "IMO IBC Code Chapter 17: Summary of minimum requirements", "New Zealand Hazardous Substances and New Organisms (HSNO) Act - Chemicals (single components)"	
2,2,4-trimethyl-1,3-pentanediol diisobutyrate(6846-50-0) is found on the following regulatory lists	"New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data", "New Zealand Inventory of Chemicals (NZIoC)", "FisherTransport Information", "OECD List of High Production Volume (HPV) Chemicals", "Sigma-AldrichTransport Information", "OECD Existing Chemicals Database", "GESAMP/EHS Composite List - GESAMP Hazard Profiles", "New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals", "IMO IBC Code Chapter 17: Summary of minimum requirements", "International Fragrance Association (IFRA) Survey: Transparency List", "New Zealand Hazardous Substances and New Organisms (HSNO) Act - Chemicals (single components)"	
4,4'-diphenylmethane diisocyanate (MDI)(101-68-8) is found on the following regulatory lists	"New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data", "New Zealand Inventory of Chemicals (NZIoC)", "FisherTransport Information", "OECD List of High Production Volume (HPV) Chemicals", "International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs", "New Zealand Workplace Exposure Standards (WES)", "Sigma- AldrichTransport Information", "OECD Existing Chemicals Database", "GESAMP/EHS Composite List - GESAMP Hazard Profiles", "International Air Transport Association (IATA) Dangerous Goods Regulations", "New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals", "IMO IBC Code Chapter 17: Summary of minimum requirements", "New Zealand Hazardous Substances and New Organisms (HSNO) Act - Chemicals (single components)"	
2,2,4-trimethyl-1,3-pentanediol diisobutyrate(6846-50-0) is found on the following regulatory lists	"New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data", "New Zealand Inventory of Chemicals (NZIoC)", "FisherTransport Information", "OECD List of High Production Volume (HPV) Chemicals", "Sigma-AldrichTransport Information", "OECD Existing Chemicals Database", "GESAMP/EHS Composite List - GESAMP Hazard Profiles", "New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals", "IMO IBC Code Chapter 17: Summary of minimum requirements", "International Fragrance Association (IFRA) Survey: Transparency List", "New Zealand Hazardous Substances and New Organisms (HSNO) Act - Chemicals (single components)"	
tetrahydroxypropyl ethylenediamine(102-60-3) is found on the following regulatory lists	"New Zealand Inventory of Chemicals (NZIoC)","FisherTransport Information","OECD List of High Production Volume (HPV) Chemicals","Sigma-AldrichTransport Information"	
polypropylene glycol glyceryl ether(25791-96-2) is found on the following regulatory lists	"New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data", "New Zealand Inventory of Chemicals (NZIoC)", "OSPAR National List of Candidates for Substitution – Norway", "Sigma-AldrichTransport Information", "GESAMP/EHS Composite List - GESAMP Hazard Profiles", "New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals", "IMO IBC Code Chapter 17: Summary of minimum requirements", "New Zealand Hazardous Substances and New Organisms (HSNO) Act - Chemicals (single components)"	
1,4-butylene glycol(110-63-4) is found on the following regulatory lists	"New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data", "New Zealand Inventory of Chemicals (NZIoC)", "IMO MARPOL 73/78 (Annex II) - List of Other Liquid Substances", "OECD List of High Production Volume (HPV) Chemicals", "Sigma-AldrichTransport Information", "OECD Existing Chemicals Database", "GESAMP/EHS Composite List - GESAMP Hazard Profiles", "New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals", "IMO IBC Code Chapter 17: Summary of minimum requirements", "Acros Transport Information", "New Zealand Hazardous Substances and New Organisms (HSNO) Act - Chemicals (single components)"	

SECTION 16 OTHER INFORMATION

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

A list of reference resources used to assist the committee may be found at:

www.chemwatch.net/references

The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright

Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.